Showing 1407 results
-
Press release /HARMONIA seeks to identify the best therapeutic option between Kisqali and Ibrance® for patients with aggressive HER2-enriched intrinsic subtype of HR+/HER2- advanced breast cancer (ABC)…
-
Press release /Approval based on results from pivotal Phase III ASCEMBL trial, in which Scemblix® (asciminib) nearly doubled the major molecular response rate vs. Bosulif®* (bosutinib) (25.5% vs. 13.2%) with a more…
-
Press release /Progression-free response stayed consistent across age, BMI, and menopausal status in MONALEESA pooled analysis1 KISQALI is only CDK4/6i to demonstrate statistically significant overall survival (OS…
-
Story /Neurological diseases develop out of sight. Novartis neuroscientists are bringing them into the light, using human brain cells grown in the lab.
-
Press release /At six months, 30% of patients treated with Kymriah were in complete response, with a 74% relapse-free rate after onset of response; median duration of response was not reached Grade 3/4…
-
Press release /Ventes, résultat opérationnel core[2] et BPA core (tcc[2]) des activités poursuivies[1] en hausse au T1 Chiffre d'affaires net s'élevant à USD 11,9 milliards (-7%, +3% tcc)]2] Résultat…
-
Press release /Interim long-term follow-up data showed all enrolled Cohort 2 patients maintained motor function and milestones achieved during the Phase 1 START trial Mean age of follow-up since dosing…
-
Press release /Positive opinion could expand the role of Cosentyx®(secukinumab) in reducing flare risk in pediatric enthesitis-related arthritis (ERA) and psoriatic arthritis (PsA) patients in the EUSafety in these…
-
Press release /Multicenter survey results show MS patients and nurses prefer the Sensoready autoinjector pen for subcutaneous self-administration of Kesimpta over other autoinjectors for their current treatment (84…
-
Press release /Results from the ORION-8 open-label extension trial show twice-yearly* Leqvio, in addition to statin therapy, provides consistent low-density lipoprotein cholesterol (LDL-C) reduction beyond six…